Terns Pharmaceuticals filed an SC TO-T/A amendment this morning, the second iteration of a third-party tender offer document that marks active M&A negotiations for the South San Francisco biotech. The amendment follows an initial SC TO-T filing, indicating terms have shifted since the buyer first disclosed its offer. Terns closed yesterday at $7.82 per share, giving the company a market capitalization near $500 million.
The SC TO-T/A form is not routine disclosure. It appears when a third party amends the terms, timing, or structure of an acquisition offer after initial filing. The document itself is a Schedule TO filed under Section 14(d)(1) of the Securities Exchange Act, required when an acquirer seeks to purchase equity securities through a tender offer. Amendments typically reflect price adjustments, extension of offer periods, or changes to deal conditions following target board negotiation or shareholder feedback. Terns has not yet filed a corresponding DFAN14A solicitation, which would signal board recommendation to accept or reject.
Terns holds a pipeline centered on non-alcoholic steatohepatitis, led by TERN-501, a thyroid hormone receptor beta agonist that completed a Phase 2a trial in December 2023 with 48-week topline data. The company reported statistically significant reduction in liver fat and fibrosis markers, positioning the asset as a potential complement to GLP-1 agonists in metabolic liver disease. Terns also advanced TERN-601, a PPAR-delta/gamma agonist, into Phase 1 trials. The NASH space has seen compressed valuations since Madrigal's resmetirom approval in March 2024 failed to ignite the sector, leaving mid-stage biotechs trading at discounts to historical peer multiples. A tender offer at this stage suggests an acquirer sees durable value in Terns' clinical dataset or believes the market has mispriced the asset's regulatory path.
The timing matters. Terns reported $198 million in cash as of September 30, 2024, sufficient to fund operations into mid-2026 under prior guidance. That runway eliminates distressed sale pressure, meaning any tender offer reflects strategic interest rather than rescue financing. The amendment filing indicates the buyer is refining terms, likely around price per share, minimum tender condition, or regulatory clearance language. The lack of a Terns board response filing suggests the company is either in active negotiation or evaluating multiple expressions of interest. The NASH landscape has consolidated over the past eighteen months, with Viking Therapeutics and Akero Therapeutics both advancing competing assets, while legacy players like Gilead and Novo Nordisk circle earlier-stage programs for pipeline fill.
Operators should track three events over the next 30 to 45 days: a Terns Schedule 14D-9 response, which the board must file within 10 business days of the tender offer becoming effective; any second amendment to the SC TO-T, which would signal continued term negotiation or a competing bid; and insider trading disclosures on Form 4, particularly by Terns' founding management team, which would reveal whether leadership is tendering shares or holding for a higher offer. The company's next earnings call is not scheduled until early February, meaning disclosure will come through SEC filings rather than earnings commentary.
The amended tender offer is the only public fact that matters. Someone is negotiating, and the terms are still moving.
The takeaway
Terns' SC TO-T/A amendment signals live M&A negotiation with shifting terms; board response filing due within ten business days.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.